References
- ZERBAXA (ceftolozane/tazobactam) for injection, for intravenous use, prescribing information. Initial US Approval: 2014. Merck & Co., Inc. (2015).
- Shortridge D, Castanheira M, Pfaller MA, Flamm RK. 2017 Ceftolozane–tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015. Antimicrob. Agents Chemother. 61, e00465–e00517 (2017).
- Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane–tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob. Agents Chemother. 56, 3086–3091 (2012).
- Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J. Antimicrob. Chemother. 67, 2463–2469 (2012).
- Sutherland CA, Nicolau DP. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals. Clin. Ther. 37(7), 1564–1571 (2015).
- Li Bassi G, Nicolau D, Senussi T et al. Characterization of the pharmacokinetic/pharmacodynamic profile of ceftolozane in an animal model of severe P. aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 195, A3915 (2017).
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for industry bioanalytical method validation. May (2001). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.